Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Phenex Pharmaceuticals
Biotech
Gilead 'strikes out' in NASH with phase 2 flop: analysts
Gilead's NASH prospects firsocotat and cilofexor failed to move the needle on liver scarring in a phase 2 study, on their own or in combination.
Amirah Al Idrus
Dec 16, 2019 11:01am
Gilead's FXR drug posts positive phase 2 data in liver condition
Nov 9, 2018 11:12am
Chutes & Ladders: Pfenex CEO resigns after in-house investigation
Jan 27, 2017 1:57pm
